Search clinical trials for: ASN004

Total 84 results

Kirilys Therapeutics Inc.

Active, not recruiting

Study of ASN004 in Patients With Advanced Solid Tumors (ASN004)

Solid Tumor

United States
Asana BioSciences

Completed

A Study of ASN007 in Patients With Advanced Solid Tumors

Cancer | Neoplasm Metastasis | Pancreatic Cancer | Metastatic Cancer | Metastatic Lung Cancer | Pancreas Adenocarcinoma | Metastatic Melanoma | Colon Cancer | Colonic Neoplasms | Pancreas Cancer | Non Small Cell Lung Cancer Metastatic | Neoplasm | Pancreas Neoplasm | Metastatic Pancreatic Cancer | Metastatic Colon Cancer and other conditions

United States
TrialSpark

Completed

A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis

Dermatitis, Atopic | Pruritus

United States
Asana BioSciences

Terminated

Study of ASN003 in Subjects With Advanced Solid Tumors

Melanoma | Neoplasms | Colorectal Neoplasm | Carcinoma, Non-small Cell Lung

United States
Asana BioSciences

Terminated

A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors

Lymphoma, Follicular | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin | Cancer | Lymphoma, Malignant | Myelofibrosis | Lymphoma, Mantle-Cell | Chronic Lymphocytic Leukemia | Peripheral T-Cell Lymphoma | Tumor | Neoplasm | B-Cell Chronic Lymphocytic Leukemia | Leukemia, Lymphocytic, Chronic | Idiopathic Myelofibrosis and other conditions

United States, Argentina
ASLAN Pharmaceuticals

Completed

A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis

Atopic Dermatitis

Australia, Singapore, United States
Asana BioSciences

Terminated

Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada
Kirilys Therapeutics, Inc.

Completed

Phase 1 Study to Evaluate ASN002 Absorption, Metabolism, and Excretion of [14C] Following a Single Oral Dose in Healthy Male Subjects

Healthy Volunteer

United States
Asana BioSciences

Completed

Single Ascending Dose Study to Evaluate Pharmacokinetics and Food-Effect in Healthy Volunteers

Healthy Volunteers

United States
Tyligand Bioscience (Shanghai) Limited

Recruiting

TSN084 Treating Patients With Advanced Malignant Tumors

Malignant Neoplasm

China
Santalis Pharmaceuticals, Inc.
ClinDatrix, Inc.; Fremantle Dermatology

Withdrawn

A Trial of a Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) For Treatment of Atopic Dermatitis

Atopic Dermatitis
Cancer Research UK
Cancer Society Auckland

Completed

Study of DMXAA (Now Known as ASA404) in Solid Tumors (DMXAA)

Solid Tumors
Asana BioSciences

Completed

Study to Evaluate ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema

Chronic Hand Dermatitis

United States, Canada
Asana BioSciences

Completed

Study to Evaluate ASN008 Topical Gel (TG)

Dermatitis, Atopic | Pruritus | Dermatitis Eczema

United States, Canada
Tyligand Bioscience (Shanghai) Limited

Recruiting

Phase I Study of TSN084 in Patients With Advanced Malignant Tumors.

Cancer (With or Without Metastasis)

United States
ASLAN Pharmaceuticals
Iqvia Pty Ltd

Completed

Study of ASLAN004 in Healthy Subjects

Allergic Disorder

Singapore
ASLAN Pharmaceuticals

Recruiting

Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab

Atopic Dermatitis

United States, Canada
Asana BioSciences

Completed

Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)

Atopic Dermatitis

United States, Germany, Canada
Asana BioSciences

Completed

A Study To Evaluate ASN002 In Subjects With Atopic Dermatitis

Dermatitis, Atopic | Dermatitis, Eczematous | Dermatitis Eczema

United States, Canada
Asana BioSciences

Terminated

Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer

Prostate Cancer | Cancer of the Prostate | Neoplasms, Prostate | Prostatic Cancer | Neoplasms, Prostatic | Prostate Neoplasms, Castration-resistant

United States
Synermore Biologics Co., Ltd.
Synermore Biologics USA Limited

Active, not recruiting

A Study to Find the MTD of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People in Patients With Epithelial Cancers With EGFR Expressions

Solid Tumor | Epithelial Carcinoma

United States
Santalis Pharmaceuticals, Inc.
Derm Research, PLLC; ClinDatrix, Inc.; Texas Dermatology and Laser Specialists; Clinical Trials of Texas, Inc... and other collaborators

Completed

A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) For Treatment of Atopic Dermatitis

Eczema | Atopic Dermatitis

United States
Synermore Biologics Co., Ltd.

Completed

Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors (SYN004_Ph_1)

Colon Cancer, Breast Cancer, Cancer of the Head and Neck

United States
Novartis Pharmaceuticals

Terminated

An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function

Histologically-proven and Radiologically-confirmed Solid Tumors

Italy, New Zealand
Novartis Pharmaceuticals

Completed

An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

Japan
S-Infinity Pharmaceuticals Co., Ltd

Not yet recruiting

A Phase I Study of XH-S004 in Healthy Volunteers

Healthy Adults

China
ASLAN Pharmaceuticals

Completed

Phase 2b Study of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

United States, Australia, Singapore, India, Canada, New Zealand, Dominican Republic, Poland
University of California, San Francisco
Novartis Pharmaceuticals

Withdrawn

ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors

Tumors

United States
Novartis Pharmaceuticals

Terminated

An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404

Metastatic Cancer With Impaired Renal Function | Metastatic Cancer With Normal Renal Function

Belgium
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co...

Recruiting

A Study of FZ-AD004 in Patients With Advanced Solid Tumors

Advanced and Metastatic Solid Tumor

China
Arsanis, Inc.

Terminated

Prevention of S. Aureus Pneumonia Study in Mechanically Ventilated Subjects Who Are Heavily Colonized With S. Aureus.

Pneumonia, Ventilator-associated | Pneumonia, Staphylococcal

United States, Spain, France, Czechia, Portugal, Israel, Romania, Russian Federation, Hungary, Poland, Ukraine, India, Austria, Georgia, Serbia, South Africa
Novartis Pharmaceuticals

Completed

Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors

Advanced or Recurrent Solid Tumors

Japan
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH

Recruiting

A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors

Liver Cancer, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Cervical Cancer, MSI-H Colorectal Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Study of JS004 Combined With Toripalimab for Advanced Lung Cancer

Advanced Lung Cancer

China
GlaxoSmithKline

Completed

Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.

Infections, Papillomavirus

Belgium, United States
Novartis Pharmaceuticals

Terminated

A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal Function

Metastatic Cancer

United States
Antisoma Research

Completed

Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer

Prostate Cancer

United States
TopAlliance Biosciences
Shanghai Junshi Bioscience Co., Ltd.; CTI Clinical Trial and Consulting Services

Recruiting

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

Metastatic Solid Tumor | Advanced Unresectable Solid Tumor

United States
Novartis Pharmaceuticals

Terminated

A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors

Advanced Solid Tumors

New Zealand
Novartis Pharmaceuticals

Terminated

Safety and Pharmacokinetics of ASA404 When Given Together With Fluvoxamine, a Selective Serotonin Receptor Reuptake Inhibitor and CYP1A2 Inhibitor

Solid Tumors

United States
GlaxoSmithKline

Completed

Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV Vaccine in Female Subjects Aged 10-14 Years

Infections, Papillomavirus

Korea, Republic of
Kyberg Vital GmbH

Completed

Dietary Intervention of Stress-Induced Neurovegetative Disorders With a Specific Amino Acid Composition (asn01) (asn01)

Nervous System Disorder | Imbalance of Constituents of Food Intake

Germany
GlaxoSmithKline

Completed

A Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years

Infections, Papillomavirus

Hong Kong
Shanghai Junshi Bioscience Co., Ltd.

Completed

The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNC

Nasopharyngeal Carcinoma | Head and Neck Squamous Cell Carcinom

China
GlaxoSmithKline

Completed

Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolescent Women With GSK Bio HPV-16/18.

Infections, Papillomavirus

Taiwan, Spain, Germany, Colombia, France, Sweden, Australia, Korea, Republic of, Honduras, Czech Republic, Norway, Panama
GlaxoSmithKline

Completed

Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to Prevent Cervical Infection in Young Adults

Infections, Papillomavirus

Canada, United States, Brazil
GlaxoSmithKline

Completed

Human Papilloma Virus Vaccine Consistency and Non-inferiority Trial in Young Adult Women With GSK Bio HPV-16/18

Infections, Papillomavirus

Finland, Russian Federation, Denmark, Greece, Netherlands, Estonia
GlaxoSmithKline

Completed

Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years

Infections, Papillomavirus

Malaysia
Hoosier Cancer Research Network
Novartis Pharmaceuticals

Withdrawn

Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma

Urothelial Carcinoma
GlaxoSmithKline

Completed

A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females

Infections, Papillomavirus

China

Search clinical trials for: ASN004

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations